The HCT/P Modernization Act of 2024
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The HCT/P Modernization Act of 2024 is a House bill introduced in the 118th Congress focused on updating regulations or policies related to human cells, tissues, and cellular and tissue-based products (HCT/Ps). The bill was referred to the Subcommittee on Health but did not advance further and is currently classified as failed or expired. No official summary or full text is available, limiting detailed analysis of its specific provisions or changes proposed.
This bill aimed to modernize aspects of HCT/P regulation but did not progress beyond initial committee referral and is no longer active in the legislative process.
- The bill is titled 'The HCT/P Modernization Act of 2024' and was introduced in the House during the 118th Congress.
- It was referred to the Subcommittee on Health on May 10, 2024, but no further legislative action occurred.
- No official summary or full text is publicly available, restricting detailed understanding of its content.
["Potential beneficiaries could include healthcare providers, tissue banks, biotechnology companies involved in HCT/Ps, and patients receiving such products, depending on the bill's provisions."]
['Without the full text, it is unclear what implementation challenges, costs, or oversight mechanisms the bill proposed.', 'The lack of available details prevents assessment of regulatory authority changes or policy tradeoffs.']
The bill was introduced in the House and referred to a relevant subcommittee but did not advance, indicating limited legislative momentum. It falls within the health policy area, specifically concerning regulation of human cells and tissues.
Hidden impact flags detected: 1
GovScope reviewed 1 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, modernization of HCT/P regulations could influence innovation and safety standards in biotechnology and healthcare sectors.', 'Changes in regulatory frameworks might affect the speed and cost of bringing HCT/P products to market.']
The absence of a full bill text and official summary restricts comprehensive transparency and public understanding of the bill's intended regulatory changes. This limits effective oversight and informed public discourse.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.